Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

3,4-dihydroxybenzohydroxamic acid

Known as: Benzamide, N,3,4-trihydroxy-, Didox, N,3,4-trihydroxybenzamide 
A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsHydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact
Axonal pathology is a key contributor to long‐term disability in multiple sclerosis (MS), an inflammatory demyelinating disease… Expand
2015
2015
Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Tamoxifen is widely used as an adjuvant therapy for patients with estrogen receptor (ERα)–positive tumors. However, the clinical… Expand
2013
2013
AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity.
The use of adjuvant therapies in cancer treatment is rationalized by potentiating the efficacy and/or protecting from the major… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
2004
2004
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase
Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Highly Cited
2003
Highly Cited
2003
Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants
Objective: To determine the role of oxidative stress in mediating HIV dementia and to identify novel therapeutic compounds that… Expand
  • figure 2
  • figure 1
  • figure 5
  • figure 6
2003
2003
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
PurposeTemozolomide (TMZ), an oral alkylating agent with good penetration of the blood-brain barrier, has shown efficacy in the… Expand
  • figure 1
  • table 1
  • figure 2
2001
2001
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
OBJECTIVE Amidox and didox are two polyhydroxy-substituted benzohydroxamic acid derivatives that belong to a new class of… Expand
1991
1991
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Didox and Amidox inhibit L1210 cell growth in culture. At least one of the mechanisms in the mode(s) of action of the compounds… Expand
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the… Expand
  • table II
  • table I
  • figure I
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE